Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $87.1429.

Several analysts have commented on ESTA shares. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Canaccord Genuity Group lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Stephens lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th.

Establishment Labs Price Performance

ESTA stock opened at $72.19 on Tuesday. The stock has a market capitalization of $2.12 billion, a P/E ratio of -48.45 and a beta of 1.12. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. Establishment Labs has a one year low of $33.35 and a one year high of $83.31. The company has a 50 day moving average price of $64.76 and a two-hundred day moving average price of $68.24.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm’s revenue was up 44.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.70) earnings per share. As a group, sell-side analysts expect that Establishment Labs will post -1.07 EPS for the current year.

Insider Buying and Selling at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders have sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is owned by company insiders.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds have recently made changes to their positions in ESTA. KBC Group NV acquired a new position in shares of Establishment Labs in the 1st quarter valued at $28,000. Quarry LP acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $34,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs in the 4th quarter valued at $47,000. State of Wyoming acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $71,000. Finally, Osaic Holdings Inc. lifted its holdings in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.